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Summary
BACKGROUND Cushing's disease is characterized by
abnormalities of immune function.
OBJECTIVE To evaluate the prevalence of autoim-
mune thyroid diseases in patients with Cushing's
disease (CD), after successful treatment and the pos-
sible association between previous nodular goitre or
positive thyroid autoantibodies during the active
phase of CD and the subsequent development of
autoimmune thyroid diseases after cure.
SUBJECTS AND METHODS Twenty patients with CD
and 40 sex- and age-matched healthy controls were
considered for the study. In CD patients, thyroid
ultrasonography and measurement of circulating
free thyroxine (fT4), free triiodothyronine (fT3), thyroid
stimulating hormone (TSH), antithyroglobulin (anti-
Tg) and antithyroperoxidase (anti-TPO) antibodies
were performed at diagnosis and 6 months after dis-
ease cure while in controls they were performed only
at study entry.
RESULTS Serum fT3, and fT4 levels were similar in
patients, either during the active phase or after cure of
the disease, and controls. Conversely, in the patients,
serum TSH levels were signi®cantly lower during
active disease (0´4 6 0´05 mU/l, P 0´001) and signi®-
cantly higher after disease cure (4´7 6 0´1 mU/l,
P < 0´001) than in controls (2´3 6 0´4 mU/l). Four
patients (20%) and 11 controls (27´5%) had positive
anti-Tg and/or anti-TPO titre at study entry, while eight
patients (40%) developed positive anti-Tg and/or anti-
TPO titre after disease cure. The prevalence of
positive antithyroid antibodies titre in cured CD
patients was signi®cantly higher than that observed
in the same patients during the active disease
(P 0´008) and in controls (P 0´031). A signi®cantly
higher prevalence of autoimmune thyroiditis was
found in patients cured from CD (35%) than in patients
with active CD (0%) (P 0´016) and in controls (10%)
(P 0´031). A signi®cant association was found
between the presence of autoimmune thyroiditis
after CD cure and the presence of a previous nodular
goitre (P 0´017) or positive thyroid autoantibodies
titre (P 0´007) during the active phase of the disease.
CONCLUSION Patients successfully treated for Cush-
ing's disease have an increased prevalence of thyroid
autoimmunity and autoimmune thyroiditis as com-
pared to a control population. Therefore, patients
with hypercortisolism need an accurate evaluation
of thyroid function after remission of the disease in
order to prevent the eventual onset of subclinical or
overt post-thyroiditis hypothyroidism.
Hypercortisolism is known to exert an inhibitory action on
immune function in humans (Dougherty, 1952). In fact, patients
with endogenous hypercortisolism have involution of lymphoid
tissue mass and lymphopenia and present with an increased
susceptibility to infections (Bateman et al., 1989). In addition,
development or exacerbation of autoimmune diseases were
reported to occur in patients with hypercortisolism after cure
(McGregor, 1990). Particularly, exacerbation of coeliac disease
(Candrina & Di Stefano, 1993) and development of sarcoidosis
(Steuer et al., 1995) or lupus erythematosus (Naguchi et al.,
1998) were reported in two different patients after correction of
hypercortisolism due either to an ACTH-secreting pituitary
adenoma or to a glucocorticoid-secreting adrenocortical
adenoma, respectively. The onset of autoimmune thyroid
disease was also reported in three patients with hypercortiso-
lism of different aetiology after successful cure of the disease
(Takasu et al., 1990; Takasu et al., 1993). On the other
hand, both endogenous and exogenous hypercortisolism, are
known to be associated to several abnormalities of thyroid
function (Ingbar, 1953; Gamsted et al., Jarnerotm, 1981;
Cavalieri et al., Castle, 1984; Rubello et al., 1992) and
Cushing's disease (CD), was recently found to be associated
with an increased prevalence of nodular thyroid disease (Invitti
et al., 1995).
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This study evaluated the prevalence of autoimmune thyroid
disease or thyroid autoantibodies after the successful cure of
CD in 20 patients and compared this prevalence to that of the
same patients at the time of CD diagnosis as well as to that of a
control population. The possibility that thyroid autoimmunity,
developed after CD cure, could be related to pre-existent




In this study were considered all the patients admitted to our
Department in the last 7 years for hypercortisolism, and
diagnosed as CD, who achieved a successful cure for at least
6 months. Among 30 patients, undergoing a complete thyroid
screening, including thyroid hormone and autoantibody assays
and thyroid ultrasonography, complete records either during the
active disease or after disease cure were obtained in 20 patients
(four males, 16 females; 13±38 years old). The data from these
20 CD patients were included in this study. Forty healthy
subjects (eight males, 32 females; 13±38 years old), coming
from the same geographical area as the patients were used as
control group. Controls were unselected apart from the exclusion
criteria of those genetically related to the patients and those with
documented endogenous or exogenous hypercortisolism. The
controls were enrolled for the study during the last 3 years.
The diagnosis of CD was based on the following criteria: (1)
increased excretion of daily urinary cortisol with inappropri-
ately high plasma ACTH concentrations; (2) increased serum
cortisol concentrations with lack of physiological circadian
rhythm; (3) failure of urinary and serum cortisol suppression
after low dose but a greater than 50% decrease after high dose
dexamethasone test. A pituitary adenoma was documented in
all patients by computed tomography, magnetic resonance
imaging or inferior petrosal sinus sampling, performed as
previously described (Old®eld et al., 1991; Colao et al., 1996;
Colao et al., 1998). Cure of CD was established on the basis of
the following criteria: (1) plasma ACTH concentrations and
daily urinary cortisol excretion below or within the normal
range; (2) serum cortisol concentrations below or within the
normal range with restoration of circadian rhythm; (3)
suppression of urinary and serum cortisol concentrations after
low-dose dexamethasone test (Colao et al., 1999b).
All patients were submitted to surgical selective resection of
the ACTH-secreting pituitary adenoma by transsphenoidal
approach. The results of histology and immunohistochemistry
on the surgically removed pituitary adenoma con®rmed in all
patients the diagnosis of CD. After surgery, 14 patients had
remission of the disease whereas the remaining six had
persistent disease and underwent pituitary radiotherapy,
which induced remission of the disease in ®ve patients after
1±3 years. The remaining patient was subjected to bilateral
adrenalectomy. This patient and three others who had
developed postsurgical or postradiation hypocortisolism
received replacement therapy with cortisone acetate at standard
doses (12´5±37´5 mg/day). No residual anterior pituitary
de®ciencies were recorded after treatment in the 20 patients
except one woman who developed hypogonadism and diabetes
insipidus, treated with oestrogen and progesterone at standard
doses and desmopressin at the dose of 15 mg/day. The adequacy
of replacement therapy was periodically monitored during
follow-up measuring blood pressure, serum electrolyte levels,
daily water balance and regularity of menses. All patients also
underwent an arginine plus GH-releasing hormone test and/or
insulin tolerance test after CD cure to evaluate residual GH
secretion (Colao et al., 1999a). GH de®ciency was recorded in
four patients, who were given human recombinant GH at the
dose of 0´0125 U/kg/day. All patients had been followed-up at
least twice yearly after CD cure to verify the complete and
persistent control of cortisol secretion and to assess the
development of pituitary insuf®ciencies. Patients' pro®le at
diagnosis of CD is shown in Table 1.
Protocol of the study
In all patients, thyroid ultrasonography (USG) and measure-
ment of circulating free thyroxine (fT4), free triiodothyronine
(fT3), thyroid stimulating hormone (TSH), antithyroglobulin
(anti-Tg) and antithyroperoxidase (anti-TPO) antibodies, were
performed at diagnosis and 6 months after the cure of the disease
while in controls they were performed only at study entry.
Assays
Serum fT4, fT3, TSH, anti-Tg and anti-TPO levels had been
measured by immunoassay using commercial kits. The normal
ranges were: fT4: 9´1±23´8 pmol/L; fT3: 2´5±5´2 pmol/L; TSH:
0´5±4´7 mU/l; anti-Tg and anti-TPO: 0±100 U/ml. anti-Tg and
anti-TPO titres 3 standard deviations above the mean were
considered as positive.
Ultrasonography study
The USG examination of the thyroid was carried out by a
commercially available real-time instrument using a 7´5-MHz
transducer. Goitre was diagnosed when the anteroposterior
diameter in both lobes was $ 20 mm. The presence of a diffuse
hypoechoic pattern with or without hyperechoic lines was
considered suggestive of thyroiditis.
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Statistical analysis
Data were expressed as mean 6 SEM. The statistical analysis
was performed by SPSS for Windows version 8´0 (Cary, NC,
USA). The comparison between the numerical data were
performed by Student's t-test for unpaired or paired data. The
P-values and 95% con®dence intervals were given for these
analysis. Comparisons between categorical data were per-
formed by x2 test with the Yates correction, Fisher exact test or
McNemar test as appropriate. The P-values were given for
these analysis. Signi®cance was set at 5%.
Results
Thyroid hormone pro®le in CD patients before and after the
disease cure is shown in Table 2. Thyroid hormones and TSH
levels in the control group were in the normal range in all cases.
Serum fT3 and fT4 levels were similar in patients with CD,
either before or after disease cure, and in controls (Table 3).
Conversely, serum TSH levels in CD patients were signi®cantly
lower during active disease and higher after disease cure, than
in controls (Table 3). Particularly, serum TSH levels were
below the normal range in 12 active patients (60%) while they
were above the normal range in ®ve cured patients (25%) and in
two controls (5%).
Serum anti-Tg and anti-TPO levels in cured patients were
signi®cantly increased compared to those observed in the same
patients during active disease and in controls, whereas they
were similar in the active CD patients and controls (Table 3).
Particularly, four patients (20%) and 11 controls (27´5%) had
positive anti-Tg and/or anti-TPO titre. After cure, eight patients
(40%) developed positive anti-Tg and/or anti-TPO titre. As a
whole, the prevalence of positive antithyroid antibodies was
signi®cantly higher after CD cure (60%) than during the active
disease (25%)(P 0´031) and in controls (27´5%)(P 0´008).
At USG, nodular goitre was found in nine patients with
active CD (45%) and six controls (20%) whereas a normal
thyroid was detected in 11 patients (55%) and 34 controls
(80%). A USG pattern suggestive of thyroiditis was detected in
none of the active patients and in four controls (10%). In cured
patients, USG con®rmed the presence of nodular goitre in nine
patients (45%), normal thyroid in six (30%), a thyroid with
normal size but with a ®nely nonhomogeneous USG pattern in
four (20%) and a USG pattern suggestive of thyroiditis in seven
patients (35%). CD patients had an increased prevalence of
nodular goitre compared to controls (P 0´027). Furthermore,
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Table 1 Clinical pro®le of patients with Cushing's disease (CD)
Urinary cortisol
Age of Disease levels (nmol/24 h)
Patient disease duration Radiological Treatment Treatments after
(sex/age) onset (years) (years) ®ndings for CD disease remission Before cure After cure
1 (f/27) 16 6 mA TS C 579 364
2 (f/50) 36 8 mA TS AH 1490 141
3 (f/19) 13 5 N TS none 1597 359
4 (f/44) 37 2 mA TS none 1007 279
5 (f/36) 25 5 mA TS none 999 149
6 (f/41) 27 8 MA TS, RT, AS none 2759 306
7 (f/39) 30 4 mA TS none 690 345
8 (f/45) 25 15 mA TS AH 894 132
9 (f/50) 25 5 mA TS none 773 270
10 (f/50) 35 10 N TS AH, GL, C, hrGH 1004 339
11 (f/47) 30 12 mA TS none 773 270
12 (m/29) 19 4 mA TS AH 1479 309
13 (f/44) 38 1 mA TS, RT AH, GL 4304 331
14 (m/20) 12 3 mA TS none 1393 284
15 (m/27) 17 4 N TS, RT, BA, AS C 2759 359
16 (f/32) 25 6 mA TS, RT, AS hrGH 1269 315
17 (f/26) 13 8 mA TS, RT none 3060 370
18 (f/27) 15 4 N TS, RT, AS hrGH 2119 94
19 (m/40) 36 3 N TS hrGH 2456 372
20 (f/24) 15 4 MA TS C, EP, D 2119 121
mA, microadenoma; MA, macroadenoma; N, negative; TS, transsphenoidal surgery; RT, radiotherapy; AS, adrenosuppressor drugs; BA, bilateral
adrenalectomy; C, cortisone acetate; EP, estroprogestinic; D, desmopressin; hrGH, human recombinant GH; AH, antihypertensive drugs; GL, glucose
lowering drugs. Urinary cortisol levels normal range, 96´5±349 nmol/24 h.
cured patients had a prevalence of USG pattern suggestive of
thyroiditis signi®cantly higher than active patients (P 0´016)
and controls (P 0´031).
A diagnosis of autoimmune thyroiditis was suspected on the
basis of the presence of positive thyroid autoantibodies and
ultrasonographic imaging suggestive of thyroiditis without any
general or local physical symptom or sign of thyroid
in¯ammation, in seven cured CD patients and in four controls.
The diagnosis of autoimmune thyroiditis (chronic lymphocytic
thyroiditis) was also con®rmed by cytological examination of a
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Table 2 Thyroid pro®le of patients with Cushing's disease (CD) before and after cure
Serum fT3 Serum fT4 Serum TSH anti-Tg titre anti-TPO titre
(pmol/l) (pmol/l) (mU/l) (U/ml) (U/ml) Thyroid USG
Before After Before After Before After Before After Before After Before After
Patient cure cure cure cure cure cure cure cure cure cure cure cure
1. 3´7 3´5 12´1 15´4 0´6 7´2 250 790 300 685 NG NG/T
2. 2´6 4´3 15´2 15´4 0´2 1´8 35 800 55 220 N D
3. 3´7 4´4 15´4 12´9 0´5 2´0 26 250 38 44 NG NG
4. 2´8 4´9 14´4 15´4 0´4 1´5 15 25 28 25 N N
5. 5´2 2´1 16´1 8´2 0´2 9´8 190 956 215 798 NG NG/T
6. 3´1 5´2 12´9 12´6 0´4 3´7 48 60 35 56 NG NG
7. 4´9 3´2 8´0 9´1 0´1 1´0 12 40 18 65 NG NG
8. 2´9 4´0 19´2 12´3 0´2 1´8 25 80 38 200 N D
9. 4´0 3´8 19´6 16´9 0´5 1´5 55 325 71 415 N D
10. 2´6 4´1 13´1 10´2 0´5 8´7 180 900 250 1050 NG NG/T
11. 3´8 3´2 12´9 9´3 0´7 1´2 18 275 56 395 N D
12. 4´6 3´5 14´8 14´0 0´4 0´5 13 27 12 35 N N
13. 5´2 3´7 11´6 10´8 0´3 7´6 18 275 85 198 NG NG/T
14. 3´5 3´8 14´9 19´4 0´1 1´5 28 56 47 81 N N
15. 3´1 2´4 14´0 15´6 0´5 2´1 62 90 77 80 N N
16. 3´4 3´8 11´2 15´7 0´6 5´9 188 350 190 544 NG NG/T
17. 4´8 6´4 10´0 22´3 0´4 4´7 44 50 35 85 N N
18. 4´9 2´0 22´3 8´1 0´7 20´8 26 650 15 2500 NG NG/T
19. 3´4 3´8 17´4 15´4 0´4 8´4 65 1700 55 895 N T
20. 3´7 3´1 14´3 12´5 0´1 3´1 25 35 18 44 N N
Mean 6 3´8 3´8 14´5 13´6 0´4 4´7 66´0 386´7 81´9 420´7
SEM 0´2 0´2 0´7 0´8 0´05 1´1* 16´2 99´7* 19´0 130´8*
N, normal; NG, nodular goiter; T, thyroiditis; D, thyroid with normal size but ®nely nonhomogeneous pattern. Hormonal normal values, serum fT3,
2´5±5´2 pmol/L; serum fT4, 9´1±23´8 pmol/l; serum TSH, 0´5±4´7 mU/l; serum antiTg and antiTPO, 0±100 U/ml. *P < 0´01 compared to baseline
evaluation.
Table 3 Comparison of thyroid pro®le values between patients with Cushing's disease and controls
Patients 95% con®dence Patients 95% con®dence 95% con®dence
before cure interval (p) after cure interval (p) Controls interval (p)
Parameters (A) A vs. C (B) B vs. A (C) B vs. C
Serum fT3 3´8 6 0´2 ± 0´79; 0´18 3´8 6 0´2 ± 0´22; 0´70 4´1 6 0´2 ± 0´56; 0´18
(pmol/l) (0´325) (1´508) (0´325)
Serum fT4 14´5 6 0´7 ± 0´61; 2´10 13´6 6 0´8 ± 2´62; 1´46 14´2 6 0´4 ± 2´2; 1´15
(pmol/l) (0´652) (0´525) (0´696)
Serum TSH 0´4 6 0´05 ± 3´04; ÿ 0´76 4´7 6 1´1 2´13; 6´57 2´3 6 0´4 0´48; 4´32
(mU/l) (0´001) (0´001) (0´015)
Anti-Tg titre 66´0 6 16´2 ± 63´83; 32´83 386´7 6 99´7 126´19; 514´91 81´5 6 15´0 158´95; 451´45
(U/ml) (0´523) (0´003) (0´000)
Anti-TPO titre 81´9 6 19´0 ± 61´13; 27´73 420´7 6 130´8 72´69; 605´01 98´6 6 12´5 135´16; 509´04
(U/ml) (0´455) (0´015) (0´001)
sample obtained after ®ne needle biopsy of the thyroid in all
seven patients. Among these patients, ®ve had serum TSH
levels higher than the normal range together with serum fT3 and
fT4 levels within normal range and without any clinical
symptom or sign. The remaining two patients and the four
controls had higher serum TSH levels and lower serum fT3 and
fT4 levels and a clinical syndrome characterized by weight
gain, skin dryness and somnolence. Subclinical hypothyroidism
was diagnosed in the ®rst group and clinical hypothyroidism in
the second group of subjects. Two of these 11 subjects had a
transient clinical syndrome suggestive of thyrotoxicosis during
the previous 3 months. All seven patients were subsequently
given replacement therapy with L-T4 at the dose of 75±125 mg/
day. Among the remaining ®ve patients with elevated serum
antithyroid antibodies levels followed-up for at least 3 years,
three normalized while in the remaining two, antithyroid
antibodies levels decreased but remained constantly above the
normal range (data not shown). None of them developed
thyroiditis. Cured patients had a prevalence of autoimmune
thyroiditis signi®cantly higher than that observed in patients
with active CD (P < 0´016) and controls (P 0´031). All the
patients with CD in the current study have been followed up for
1±3 years after the disease cure and none of the patients who
did not have an autoimmune thyroiditis during the ®rst
6 months, developed it after this period.
A signi®cant association was found between the presence of
autoimmune thyroiditis in cured patients and the presence of a
previous nodular goitre (P 0´017) or positive antithyroid
antibodies titre (P 0´007) during the active phase of CD.
Discussion
Hypercortisolism is well known to induce immunosuppression
in humans. However, no study has ever evaluated the
consequences of the resolution of hypercortisolism on
immune function with the exception of some case reports
(Takasu et al., 1990; Candrina & Di Stefano, 1993; Takasu et
al., 1993; Steuer et al., 1995) which described the onset or
exacerbation of autoimmune diseases in patients cured of
Cushing's syndrome. The current study was performed with the
aim of evaluating the prevalence of autoimmune thyroid
diseases in a series of patients with CD after at least 6 months
of successful cure in comparison to an unselected control
population and thus to investigate whether CD is a risk factor
for the development of autoimmune thyroid disease. The results
demonstrated that patients with a history of CD have an
increased prevalence of thyroid autoimmunity as compared to
controls, and frequently develop autoimmune thyroiditis during
the ®rst 6 months after the normalization of serum cortisol
levels. The probability of developing an autoimmune thyroiditis
was signi®cantly associated to the presence of a previous
nodular goitre or positive antithyroid antibodies titre during the
active phase of the disease. Furthermore, CD patients had
suppressed serum TSH levels during the active phase of the
disease, probably related to the hypercortisolism itself as
demonstrated by the normalization of hormone levels after the
disease cure in all patients, except those who developed a post-
thyroiditis hypothyroidism and had persistently elevated serum
TSH levels.
The mechanism underlying the development of thyroid
autoimmunity in CD patients after their cure is still unknown.
On the other hand, the effect of glucocorticoids on the immune
system is well known (Dougherty, 1952; Bateman et al., 1989;
McGregor, 1990). The original clinical observations on the
reduction in lymphoid-tissue mass and lymphopenia in
Cushing's syndrome and the contrasting increase in lym-
phoid-tissue mass and lymphocytosis in adrenal insuf®ciency
have been supplemented by considerable insight into the role of
glucocorticoids in modulating the immune system (McGregor,
1990). The effect of glucocorticoids on lymphocyte function is
predominantly directed on T cell proliferation, through the
inhibition of the process of interleukin-1 generation by antigen-
presenting macrophage cells and the process of interleukin-2
production by activated T cells (McGregor, 1990). The effects
on B cells seem to be less relevant. Although glucocorticoids
reduce the levels of circulating immunoglobulins, their
in¯uence on B cell function is probably related to their effect
on T cell proliferation (Dougherty, 1952; Bateman et al., 1989;
McGregor, 1990). These pieces of evidence demonstrate that
glucocorticoids strongly in¯uence the immune system, as
hypercortisolism inhibits and hypocortisolism activates the
immune function. Therefore, the observation of three hyper-
cortisolaemic patients who developed autoimmune thyroiditis
after resolution of hypercortisolism, lead to the hypothesis that
this phenomenon may be related to a rebound in immune
activity after its suppression during glucocorticoid excess
(Takasu et al., 1990; Takasu et al., 1993).
The current study included a series of patients with pituitary-
dependent hypercortisolism and con®rmed that CD patients
have an increased risk of developing thyroid autoimmunity
after the resolution of hypercortisolism. The increased
antithyroid antibody levels are transient in several cases. It
induced true chronic lymphocytic thyroiditis and subsequent
hypothyroidism especially in those cases with nodular goitre or
positive antithyroid antibodies titre at the time of the active
disease. A similar rebound in the immune response has been
observed in a physiological condition, such as in the postpartum
period. In fact, pregnancy is well known to be associated to a
reduction of lymphocyte function and improvement of various
autoimmune disease, as in active Cushing's syndrome, whereas
the postpartum period is associated to a transient rebound of
lymphocyte function and exacerbation of autoimmune diseases,
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as in cured Cushing's syndrome (Amino, 1983; Jansson &
Karlsson, 1986). Moreover, autoimmune thyroiditis was reported
to occur frequently in the postpartum period especially in those
patients with a previous diagnosis of thyroid disease and/or
autoimmunity (Amino, 1983; Jansson & Karlsson, 1986). The
causes of the suppression, during pregnancy, and the rebound,
during the postpartum period, in the immune response as well as
the onset and/or development of a postpartum autoimmune
thyroiditis are not completely understood. However, pregnancy
and postpartum represent a physiological example of environ-
mental modulation of immune function and induction of
autoimmune diseases. Similarly, CD may represent an example
of pathological environmental modulation of immune function
and autoimmune diseases. On the other hand, it may be argued
that thyroid autoimmunity has, anyway, a multifactorial origin,
with both genetic and environmental elements contributing to
its development (De Groot & Quintans, 1989). On this basis,
the fall in serum cortisol levels occurring in patients cured from
CD is likely to induce an aberrant autoimmune resp onse only in
those patients genetically predisposed to autoimmunity.
Finally, since depression was described to be associated to
increased circulating levels of thyroid autoantibodies (Pop et
al., 1998) and it represents one of the most frequent features of
Cushing's disease, the possibility that the described increased
risk of autoimmune thyroid disorders might be related to the
depression in these patients cannot be ruled out. Finally, as the
patients in the current study underwent surgery and, in some
cases, also radiotherapy, the possibility that either surgery or
radiotherapy could have in some part in¯uenced the autoanti-
body titre in our patients cannot be completely ruled out.
In conclusion, the results of this study demonstrated that
patients cured from hypercortisolism have an increased
prevalence of thyroid autoimmune disorders. Thus, Cushing's
disease patients need an accurate evaluation of thyroid function
after normalization of serum cortisol levels in order to prevent
the possible onset of subclinical/overt post-thyroiditis
hypothyroidism. The study of thyroid hormone pro®le and
ultrasonography is recommended during the 6 months after the
clinical and biochemical cure of Cushing's disease in those
patients previously having positive antithyroid antibodies and/
or a nodular goitre. Finally, the results of the current study
suggested that the patients who receive treatment with
corticosteroids for nonendocrine disease may also have an
increased risk of developing autoimmune thyroid disorders
after discontinuation of corticosteroid therapy.
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